Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
10.18632/oncotarget.28047
Saved in:
Main Authors: | Marijon, Hélène, Gery, Sigal, Chang, Hua, Landesman, Yosef, Shacham, Sharon, Lee, Dhong Hyun, de Gramont, Aimery, Koeffler, Harold Phillip |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
Impact Journals LLC
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/233145 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families
by: Kang, P., et al.
Published: (2014) -
Laboratory Verification of a BRCA1 and BRCA2 Massively Parallel Sequencing Assay from Wet Bench to Bioinformatics for Germline DNA Analysis
by: Poon, Kok-Siong, et al.
Published: (2021) -
Functional genome-wide screening identifies targets and pathways sensitizing pancreatic cancer cells to dasatinib
by: Chien W., et al.
Published: (2020) -
Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history
by: Kang, P.C.E., et al.
Published: (2014) -
The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives
by: Sng, J.-H., et al.
Published: (2014)